T. Rowe Price Associates
FLGT icon

T. Rowe Price Associates’s Fulgent Genetics FLGT Stock Holding History

T. Rowe Price Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Buy
26,674
+4,261
+19% +$92.5K ﹤0.01% 2526
2025
Q4 		$589K Buy
22,413
+1,521
+7% +$39.5K ﹤0.01% 2318
2025
Q3 		$473K Buy
20,892
+181
+0.9% +$3.73K ﹤0.01% 2376
2025
Q2 		$412K Buy
20,711
+1,104
+6% +$21.5K ﹤0.01% 2391
2025
Q1 		$332K Buy
19,607
+942
+5% +$16K ﹤0.01% 2421
2024
Q4 		$345K Buy
18,665
+3,747
+25% +$73.2K ﹤0.01% 2447
2024
Q3 		$325K Buy
14,918
+56
+0.4% +$1.25K ﹤0.01% 2443
2024
Q2 		$292K Buy
14,862
+601
+4% +$12.5K ﹤0.01% 2428
2024
Q1 		$310K Buy
14,261
+3,458
+32% +$85.9K ﹤0.01% 2419
2023
Q4 		$313K Buy
10,803
+1,448
+15% +$38.7K ﹤0.01% 2358
2023
Q3 		$251K Buy
9,355
+351
+4% +$12K ﹤0.01% 2411
2023
Q2 		$334K Buy
9,004
+1,221
+16% +$42.6K ﹤0.01% 2313
2023
Q1 		$243K Buy
7,783
+836
+12% +$26.9K ﹤0.01% 2441
2022
Q4 		$207K Buy
6,947
+316
+5% +$11.3K ﹤0.01% 2518
2022
Q3 		$253K Buy
6,631
+1,378
+26% +$69.1K ﹤0.01% 2455
2022
Q2 		$286K Buy
5,253
+620
+13% +$34.1K ﹤0.01% 2459
2022
Q1 		$289K Buy
4,633
+1,411
+44% +$92.9K ﹤0.01% 2563
2021
Q4 		$324K Sell
3,222
-3,533
-52% -$311K ﹤0.01% 2571
2021
Q3 		$608K Sell
6,755
-2
-0% -$182 ﹤0.01% 2288
2021
Q2 		$623K Buy
6,757
+1,843
+38% +$147K ﹤0.01% 2283
2021
Q1 		$475K Buy
+4,914
New +$507K ﹤0.01% 2392

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates's FLGT Position: Q1 2026 in Review

T. Rowe Price Associates increased its Fulgent Genetics (FLGT) stake by 19% in Q1 2026, buying an estimated $92.5K and bringing the position to 26,674 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

T. Rowe Price Associates first reported a position in FLGT in Q1 2021 and has held it in 21 quarters since. The position peaked at $623K in Q2 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • T. Rowe Price Associates held 26,674 shares of Fulgent Genetics worth $425K as of Q1 2026.
  • T. Rowe Price Associates bought 4,261 Fulgent Genetics shares in Q1 2026, an estimated $92.5K.
  • Fulgent Genetics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2526 holding.
  • T. Rowe Price Associates first reported a position in Fulgent Genetics in Q1 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Fulgent Genetics position peaked at $623K in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.